• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GE HealthCare Technologies Inc. to Join the Nasdaq-100 Index® Beginning June 7, 2023

    5/30/23 8:00:00 PM ET
    $FISV
    $GEHC
    $NDAQ
    Business Services
    Consumer Discretionary
    Medical Electronics
    Health Care
    Get the next $FISV alert in real time by email

    NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that GE HealthCare Technologies Inc. (NASDAQ:GEHC), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX), the Nasdaq-100 Equal Weighted Index (NASDAQ:NDXE), and the Nasdaq-100 Ex-Tech Sector Index (NASDAQ:NDXX) prior to market open on Wednesday, June 7, 2023. GE HealthCare Technologies Inc. will replace Fiserv, Inc. (NASDAQ:FISV) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. Fiserv, Inc. will also be removed from the Nasdaq-100 ESG Index (NASDAQ:NDXESG) prior to market open on Wednesday, June 7, 2023.

    For more information about the company, go to https://www.gehealthcare.com/.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -

    Media Contact: Camille Stafford, Nasdaq
    Issuer & Investor Contact:  Index Client Services, Nasdaq
      [email protected]

     



    Primary Logo

    Get the next $FISV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FISV
    $GEHC
    $NDAQ

    CompanyDatePrice TargetRatingAnalyst
    GE HealthCare Technologies Inc.
    $GEHC
    5/5/2025$73.00Sell → Neutral
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    GE HealthCare Technologies Inc.
    $GEHC
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    Nasdaq Inc.
    $NDAQ
    1/8/2025$80.00 → $98.00Hold → Buy
    Deutsche Bank
    GE HealthCare Technologies Inc.
    $GEHC
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    Nasdaq Inc.
    $NDAQ
    11/25/2024Outperform
    William Blair
    Nasdaq Inc.
    $NDAQ
    10/14/2024$82.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings